These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Dopamine agonists in the treatment of Parkinson's disease. Rinne UK Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists. Goldstein M; Engel J; Lieberman A; Regev I; Bystritsky A; Mino S J Neural Transm Suppl; 1983; 18():257-63. PubMed ID: 6135744 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085. Schneider E; Hubener K; Fischer PA Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Parkinson's disease with lergotrile mesylate. Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094 [TBL] [Abstract][Full Text] [Related]
12. Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism. Kartzinel R; Shoulson I; Calne DB Neurology; 1976 Jun; 26(6 PT 1):511-3. PubMed ID: 778655 [TBL] [Abstract][Full Text] [Related]
13. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors. Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782 [TBL] [Abstract][Full Text] [Related]